£75.15

This is the most expensive it has ever been. Walk away.

£75 today · previous high £75 · all-time low £75

VDM Verlag Tizoxanide Inhibits HCV Replication Through NS5A Hyperphosporylation

Amazon

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 10 days · 10 data points (no recent data)

Historical
Generating forecast…
£75.15 £74.99 £75.02 £75.06 £75.09 £75.13 £75.17 06 September 2026 08 September 2026 10 September 2026 12 September 2026 15 September 2026
View at Amazon ↗

Price data last checked 55 day(s) ago - refreshing...

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↑ Price chart
when this has been cheap or pricey
↑ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price Distribution

Price distribution over 10 days • 1 price levels

Days at Price
10 days 0 3 5 8 10 £75 Days at Price

Price Analysis

Most common price: £75 (10 days, 100.0%)

Price range: £75 - £75

Price levels: 1 different prices over 10 days

Description

Nitazoxanide (NTZ, Alinia®, Romark Laboratories, LC) is a licensed thiazolide anti-infective that has been in clinical development for the treatment of chronic hepatitis C, but the antiviral mechanism has remained undetermined. Here, we determined the effect of tizoxanide (TIZ, active metabolite of NTZ) on intracellular HCV proteins to reveal a mechanism of action. The overall rate of reduction of HCV proteins in HCV replicon containing cell lines treated with TIZ was consistent with loss of viral RNA template. Examination of intracellular membrane preparations (where replication of HCV is localized) from HCV replicon cell lines revealed enhanced levels of hyperphosphorylated HCV NS5A (p58) peaking after 48 hours of TIZ treatment, coincident with the initial reduction of HCV RNA. The phosphorylation state of NS5A is established as a regulator of the switch from active viral genome replication to packaging and assembly; overproduction of p58 is established as being inhibitory to HCV replication. Consistent with this model, HCV RdRp activity on nascent HCV genomes in membrane preparations from TIZ-treated cultures was also reduced.

Product Specifications

Format
paperback
Domain
Amazon UK
Release Date
22 August 2017
Listed Since
20 February 2019

Barcode

No barcode data available

Similar Products You Might Like

Arbidol: an antiviral against globally prevalent viruses: A promising antiviral strategy
76% match

Arbidol: an antiviral against globally prevalent viruses: A promising antiviral strategy

VDM Verlag

£35.91 24 Oct 2026
Hepatitis Prevention and Treatment (Milestones in Drug Therapy)
76% match

Hepatitis Prevention and Treatment (Milestones in Drug Therapy)

Birkhauser

£129.04 22 Oct 2026
Hepatitis C Virus: The Next Epidemic, An issue of Gastroenterology Clinics of North America (Volume 44-4) (The Clinics: Internal Medicine, Volume 44-4)
74% match

Hepatitis C Virus: The Next Epidemic, An issue of Gastroenterology Clinics of North America (Volume 44-4) (The Clinics: Internal Medicine, Volume 44-4)

Elsevier

£55.00 09 Sep 2026
Therapeutic Potentials of Tenofovir Alafenamide in Hepatitis B
74% match

Therapeutic Potentials of Tenofovir Alafenamide in Hepatitis B

Elsevier

£137.99 24 Oct 2026
Mechanisms involved in resistance to interferon alpha therapy in HCV
74% match

Mechanisms involved in resistance to interferon alpha therapy in HCV

LAP Lambert Academic Publishing

£74.00 04 Nov 2026
Oral Colon Targeted Drug Delivery Systems for Tinidazole: Design and Evaluation
74% match

Oral Colon Targeted Drug Delivery Systems for Tinidazole: Design and Evaluation

LAP Lambert Academic Publishing

£38.99 04 Nov 2026
Advances in Antiviral Drug Design (Volume 4)
74% match

Advances in Antiviral Drug Design (Volume 4)

Elsevier

£56.25 23 Oct 2026
Hepadnaviruses: Molecular Biology and Pathogenesis: 168 (Current Topics in Microbiology and Immunology, 168)
74% match

Hepadnaviruses: Molecular Biology and Pathogenesis: 168 (Current Topics in Microbiology and Immunology, 168)

Springer

£75.41 24 Oct 2026
Hepatitis Prevention and Treatment (Milestones in Drug Therapy)
73% match

Hepatitis Prevention and Treatment (Milestones in Drug Therapy)

Birkhauser

£108.70 22 Oct 2026
Hepatitis C Virus Protocols: 1911 (Methods in Molecular Biology, 1911)
73% match

Hepatitis C Virus Protocols: 1911 (Methods in Molecular Biology, 1911)

Humana

£141.92 03 Nov 2026
The Hepatitis B and Delta Viruses (Cold Spring Harbor Perspectives in Medicine)
73% match

The Hepatitis B and Delta Viruses (Cold Spring Harbor Perspectives in Medicine)

Cold Spring Harbor Laboratory Press

£74.90 13 Oct 2026
HCV: The Journey from Discovery to a Cure: Volume II: 32 (Topics in Medicinal Chemistry, 32)
73% match

HCV: The Journey from Discovery to a Cure: Volume II: 32 (Topics in Medicinal Chemistry, 32)

Springer

£262.55 15 Sep 2026
Antiviral RNAi: Concepts, Methods, and Applications: 721 (Methods in Molecular Biology, 721)
73% match

Antiviral RNAi: Concepts, Methods, and Applications: 721 (Methods in Molecular Biology, 721)

Humana

£113.73 04 Nov 2026
Antimicrobial Resistance: Control Mechanism, Regulation and Clinical Implications
72% match

Antimicrobial Resistance: Control Mechanism, Regulation and Clinical Implications

£112.24 02 Nov 2026
Effects of Fluoroquinolones on the Helicase Activity of HCV
72% match

Effects of Fluoroquinolones on the Helicase Activity of HCV

LAP Lambert Academic Publishing

£56.00 04 Nov 2026
Hepatitis B Virus and Liver Disease
72% match

Hepatitis B Virus and Liver Disease

Springer

£89.28 26 Oct 2026
Viral Hepatitis: Diagnosis, Therapy, and Prevention
72% match

Viral Hepatitis: Diagnosis, Therapy, and Prevention

Humana

£59.94 14 Sep 2026
Hepatitis Delta Virus: 307 (Current Topics in Microbiology and Immunology, 307)
71% match

Hepatitis Delta Virus: 307 (Current Topics in Microbiology and Immunology, 307)

Springer

£109.72 23 Oct 2026
Neisseria gonorrhoeae: Methods and Protocols: 1997 (Methods in Molecular Biology, 1997)
71% match

Neisseria gonorrhoeae: Methods and Protocols: 1997 (Methods in Molecular Biology, 1997)

Humana

£81.74 24 Oct 2026
Nipah Virus: Methods and Protocols: 2682 (Methods in Molecular Biology, 2682)
71% match

Nipah Virus: Methods and Protocols: 2682 (Methods in Molecular Biology, 2682)

Humana

£141.67 30 Aug 2026
HIV and Liver Disease
71% match

HIV and Liver Disease

Springer

£80.67 22 Oct 2026
Vaccines for Latent Viral Infections
71% match

Vaccines for Latent Viral Infections

Bentham Science Publishers

£63.41 03 Nov 2026
Human Antibody Therapeutics For Viral Disease: 317 (Current Topics in Microbiology and Immunology, 317)
71% match

Human Antibody Therapeutics For Viral Disease: 317 (Current Topics in Microbiology and Immunology, 317)

Springer

£108.18 27 Oct 2026
Viral Hepatitis in Children: Unique Features and Opportunities (Clinical Gastroenterology)
71% match

Viral Hepatitis in Children: Unique Features and Opportunities (Clinical Gastroenterology)

Humana

£103.48 03 Nov 2026